Download full-text PDF |
Source |
---|
Vascular
December 2024
Division of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padova, Italy.
Background: Superior vena cava syndrome (SVCs) is a common complication in hemodialysis patients due to central vein occlusions, often caused by prior catheterizations. Management can be challenging.
Objective: To describe a successful endovascular approach to managing SVCs caused by right innominate vein (RIV) occlusion in a hemodialysis patient with a non-functional LeVeen shunt.
Catheter Cardiovasc Interv
November 2024
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
No Shinkei Geka
September 2024
Department of Neurosurgery, Hokkaido University Graduate School of Medicine.
Delayed cerebral vasospasm is a major complication following subarachnoid hemorrhage and a primary cause of delayed cerebral ischemia. While various preventive treatments exist, some patients still develop severe vasospasm, highlighting the need for better rescue therapies. This article explores endovascular treatment as a rescue option for vasospasm, focusing on the clinical characteristics and roles of intra-arterial vasodilator injection therapy and percutaneous transluminal angioplasty(PTA).
View Article and Find Full Text PDFAsian J Surg
September 2024
Department of Ophthalmology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, 441000, China. Electronic address:
Lancet
September 2024
Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Electronic address:
Background: The long-term impact of drug-coated balloon (DCB) angioplasty for the treatment of patients with de novo coronary artery lesions remains uncertain. We aimed to assess the non-inferiority of DCB angioplasty with rescue stenting to intended drug-eluting stent (DES) deployment for patients with de novo, non-complex coronary artery lesions.
Methods: REC-CAGEFREE I was an open-label, randomised, non-inferiority trial conducted at 43 sites in China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!